Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
7.39% $0.0218
America/New_York / 29 feb 2024 @ 15:53
FUNDAMENTALS | |
---|---|
MarketCap: | 0.950 mill |
EPS: | -94.13 |
P/E: | -0.0002 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 43.59 mill |
Avg Daily Volume: | 0.425 mill |
RATING 2024-02-29 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Neutral | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0002 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.0002 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.0130 - 0.0210 ( +/- 23.53%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-09 | Mcandrew Natalie | Buy | 0 | |
2023-07-03 | Kim Yong Chan | Sell | 0 | Common Stock |
2023-07-03 | Kim Yong Chan | Sell | 4 520 066 | Series X Preferred Stock |
2022-12-15 | Henwood Geraldine | Buy | 1 200 | Common Stock |
2022-06-15 | Ashton William | Buy | 39 473 | Common Stock |
INSIDER POWER |
---|
-98.28 |
Last 86 transactions |
Buy: 13 000 393 | Sell: 13 896 192 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0218 (7.39% ) |
Volume | 0.311 mill |
Avg. Vol. | 0.425 mill |
% of Avg. Vol | 73.17 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.